Tag: abbott
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for...
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration...
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year...
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of...
Abbott’s Esprit BTK scaffold system given US FDA approval for CLTI...
Abbott has announced that the US Food and Drug Administration (FDA) has approved the Esprit BTK everolimus-eluting resorbable scaffold system (Esprit BTK system), a...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough...
Results of the LIFE-BTK randomised controlled trial have just been presented at TCT 2023 (23–26 October, San Francisco, USA). The data show that, in...
Interventional News’ top 10 most popular stories of February 2023
Interventional News’ most popular stories for the month of February included news from the Pan Arab Interventional Radiology Society annual meeting (PAIRS; 11–14 February,...
No safety concerns and favourable patency at two years with Absorb...
The Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) can be used for the treatment of chronic limb-threatening ischaemia (CLTI) patients in infrapopliteal arteries with...
First patients enrolled in SUPERSURG study of Supera peripheral stent system
ID3 Medical Belgium has announced the first two enrolments in the SUPERSURG study to investigate the safety and efficacy of Abbott's Supera peripheral stent...
VIVA 2019: ABSORB BVS achieves “excellent” long-term patency and freedom from...
Ramon Varcoe today announced positive five-year results of the ABSORB BTK trial at the 2019 Vascular Interventional Advances conference (VIVA) in Las Vegas, USA...
InspireMD announces expansion of its distribution network for CGuard EPS in...
InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...
Terumo completes acquisition of vascular closure business and other assets of...
Terumo has announced that it has completed its acquisition of certain assets owned by Abbott and St Jude Medical on 20 January 2017 (North...
Abbott completes St Jude Medical acquisition
Abbott announced on 4 January 2017 that it has completed the acquisition of St Jude Medical.
“Abbott has a strong track record of successfully integrating...
Terumo signs to acquire St Jude Medical and Abbott’s vascular closure...
Terumo has reached an agreement with Abbott and St Jude Medical to acquire certain products owned by both for a total of US$1.12 billion.
Based...
St Jude Medical shareholders approve merger with Abbott
St Jude Medical has announced that, based on the preliminary voting results from St Jude Medical’s Annual Meeting of Shareholders held on 26 October,...
Terumo looks to buy vascular closure and electrophysiology businesses from St...
Abbott and St Jude Medical have announced an agreement in principle to sell certain products to Terumo Corporation.The agreement is an important step toward...
